# STEPS Trial - Spheramine Safety and Efficacy Study

> **NCT00206687** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 71 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **BIOLOGICAL:** Spheramine (BAY86-5280)
- **PROCEDURE:** Placebo

## Key facts

- **NCT ID:** NCT00206687
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01-08
- **Primary completion:** 2012-05-14
- **Final completion:** 2012-05-14
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Study was completed, only life long extended follow-up phase was discontinued after 12 years.
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206687, "STEPS Trial - Spheramine Safety and Efficacy Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00206687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*